Lea R Eisenbach

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4701430/publications.pdf

Version: 2024-02-01

85 3,589 29 59
papers citations h-index g-index

87 87 87 4488
all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	DAP kinase links the control of apoptosis to metastasis. Nature, 1997, 390, 180-184.	27.8	370
2	Knockdown of ALR (MLL2) Reveals ALR Target Genes and Leads to Alterations in Cell Adhesion and Growth. Molecular and Cellular Biology, 2007, 27, 1889-1903.	2.3	347
3	UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma. Cell, 2019, 179, 219-235.e21.	28.9	270
4	CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma. Nature, 1994, 369, 67-71.	27.8	254
5	CD66a Interactions Between Human Melanoma and NK Cells: A Novel Class I MHC-Independent Inhibitory Mechanism of Cytotoxicity. Journal of Immunology, 2002, 168, 2803-2810.	0.8	163
6	Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides. Nature Medicine, 1995, 1, 1179-1183.	30.7	143
7	A Novel Lytic Peptide Composed of dl-Amino Acids Selectively Kills Cancer Cells in Culture and in Mice. Journal of Biological Chemistry, 2003, 278, 21018-21023.	3.4	136
8	MHC imbalance and metastatic spread in Lewis lung carcinoma clones. International Journal of Cancer, 1983, 32, 113-120.	5.1	126
9	The differential expression of H-2K versus H-2D antigens, distinguishing high- metastatic from low-metastatic clones, is correlated with the immunogenic properties of the tumor cells. International Journal of Cancer, 1984, 34, 567-573.	5.1	106
10	Analysis of endogenous peptides bound by soluble MHC class I molecules: a novel approach for identifying tumor-specific antigens. European Journal of Immunology, 2002, 32, 213-222.	2.9	103
11	Combined Dendritic Cell Cryotherapy of Tumor Induces Systemic Antimetastatic Immunity. Clinical Cancer Research, 2005, 11, 4955-4961.	7.0	103
12	Anti-metastatic vaccination of tumor-bearing mice with il-2-gene-inserted tumor cells. International Journal of Cancer, 1993, 53, 471-477.	5.1	96
13	MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitope. European Journal of Immunology, 1999, 29, 3295-3301.	2.9	79
14	PACT: cloning and characterization of a cellular p53 binding protein that interacts with Rb. Oncogene, 1997, 14, 145-155.	5.9	66
15	Human CTL Epitopes Prostatic Acid Phosphatase-3 and Six-Transmembrane Epithelial Antigen of Prostate-3 as Candidates for Prostate Cancer Immunotherapy. Cancer Research, 2005, 65, 6435-6442.	0.9	66
16	The mechanisms controlling NK cell autoreactivity in TAP2-deficient patients. Blood, 2004, 103, 1770-1778.	1.4	62
17	Selective Targeting of Melanoma and APCs Using a Recombinant Antibody with TCR-Like Specificity Directed Toward a Melanoma Differentiation Antigen. Journal of Immunology, 2003, 171, 2197-2207.	0.8	53
18	Rapid alteration of c-mycand c-junexpression in leukemic cells induced to differentiate by a butyric acid prodrug. FEBS Letters, 1993, 328, 225-229.	2.8	49

#	Article	IF	CITATIONS
19	Direct detection and quantitation of a distinct T-cell epitope derived from tumor-specific epithelial cell-associated mucin using human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells. Cancer Research, 2002, 62, 5835-44.	0.9	44
20	Effective anti-metastatic melanoma vaccination with tumor cells transfected with MHC genes and/or infected with newcastle disease virus (NDV). International Journal of Cancer, 1994, 59, 796-801.	5.1	43
21	Trogocytosis of MHC-I/Peptide Complexes Derived from Tumors and Infected Cells Enhances Dendritic Cell Cross-Priming and Promotes Adaptive T Cell Responses. PLoS ONE, 2008, 3, e3097.	2.5	41
22	Novel breast-tumor-associated MUC1-derived peptides: Characterization in Dbâ^²/â^² \tilde{A} — \hat{l}^2 2 microglobulin (\hat{l}^2 2m) null mice transgenic for a chimeric HLA-A2.1/Db- \hat{l}^2 2 microglobulin single chain. International Journal of Cancer, 2000, 85, 391-397.	5.1	40
23	The human <i>1â€8D</i> gene (<i>IFITM2</i>) is a novel <i>p53</i> independent proâ€apoptotic gene. International Journal of Cancer, 2009, 125, 2810-2819.	5.1	40
24	Immunotherapy Via Gene Therapy. Journal of Immunotherapy, 1993, 14, 191-201.	2.4	38
25	O-glycosylated versus non-glycosylated MUC1-derived peptides as potential targets for cytotoxic immunotherapy of carcinoma. Clinical and Experimental Immunology, 2006, 143, 139-149.	2.6	38
26	The antiâ€inflammatory IFITM genes ameliorate colitis and partially protect from tumorigenesis by changing immunity and microbiota. Immunology and Cell Biology, 2018, 96, 284-297.	2.3	38
27	Capture of Tumor Cell Membranes by Trogocytosis Facilitates Detection and Isolation of Tumor-Specific Functional CTLs. Cancer Research, 2008, 68, 2006-2013.	0.9	37
28	A Systems Immunology Approach to the Host-Tumor Interaction: Large-Scale Patterns of Natural Autoantibodies Distinguish Healthy and Tumor-Bearing Mice. PLoS ONE, 2009, 4, e6053.	2.5	36
29	Membrane-Anchored \hat{I}^2 2-Microglobulin Stabilizes a Highly Receptive State of MHC Class I Molecules. Journal of Immunology, 2005, 174, 2116-2123.	0.8	30
30	Characterization of novel breast carcinoma–associated BA46-derived peptides in HLA-A2.1/Db-β2mtransgenic mice. Journal of Clinical Investigation, 2002, 110, 453-462.	8.2	30
31	Exuberated Numbers of Tumor-Specific T Cells Result in Tumor Escape. Cancer Research, 2008, 68, 3450-3457.	0.9	29
32	Abrogation of B16 Melanoma Metastases by Long-Term Low-Dose Interleukin-6 Therapy. Journal of Immunotherapy, 1993, 13, 98-109.	2.4	27
33	Pneumococcal Capsular Polysaccharide Is Immunogenic When Present on the Surface of Macrophages and Dendritic Cells: TLR4 Signaling Induced by a Conjugate Vaccine or by Lipopolysaccharide Is Conducive. Journal of Immunology, 2008, 180, 2409-2418.	0.8	25
34	Cryoimmunotherapy with local co-administration of ex vivo generated dendritic cells and CpG-ODN immune adjuvant, elicits a specific antitumor immunity. Cancer Immunology, Immunotherapy, 2014, 63, 369-380.	4.2	25
35	Immunization by gamma-IFN-treated B16-F10.9 melanoma cells protects against metastatic spread of the parental tumor. International Journal of Cancer, 1991, 47, 54-60.	5.1	23
36	Antitumor vaccination using peptide based vaccines. Immunology Letters, 2000, 74, 27-34.	2.5	22

#	Article	IF	Citations
37	In vivo rejection of tumor cells dependent on CD8 cells that kill independently of perforin and FasL. Cancer Gene Therapy, 2004, 11, 237-248.	4.6	22
38	Induction of Antitumor Immunity with Modified Autologous Cells Expressing Membrane-Bound Murine Cytokines. Journal of Interferon and Cytokine Research, 1999, 19, 1391-1401.	1.2	21
39	Induction of Antitumor Immunity by CTL Epitopes Genetically Linked to Membrane-Anchored Î ² 2-Microglobulin. Journal of Immunology, 2006, 176, 217-224.	0.8	20
40	Split Immunity: Immune Inhibition of Rat Gliomas by Subcutaneous Exposure to Unmodified Live Tumor Cells. Journal of Immunology, 2011, 187, 5452-5462.	0.8	19
41	Induction of antitumor immunity by proteasome-inhibited syngeneic fibroblasts pulsed with a modified TAA peptide. International Journal of Cancer, 2000, 85, 236-242.	5.1	17
42	Nanoparticulate vaccine inhibits tumor growth via improved T cell recruitment into melanoma and huHER2 breast cancer. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 835-847.	3.3	17
43	Antimetastatic vaccination against Lewis lung carcinoma with autologous tumor cells modified to express murine Interleukin 12. Clinical and Experimental Metastasis, 1998, 16, 623-632.	3.3	16
44	mRNA-transfected Dendritic Cells Expressing Polypeptides That Link MHC-I Presentation to Constitutive TLR4 Activation Confer Tumor Immunity. Molecular Therapy, 2015, 23, 1391-1400.	8.2	16
45	Combined therapy with IL-6 and inactivated tumor cells suppresses metastasis in mice bearing 3LL lung carcinomas. International Journal of Cancer, 1993, 53, 812-818.	5.1	15
46	Expression of functionally intact pdgf- $\hat{l}\pm$ receptors in highly metastatic 3ll lewis lung carcinoma cells. International Journal of Cancer, 1993, 53, 315-322.	5.1	14
47	Non-replicating mucosal and systemic vaccines: quantitative and qualitative differences in the Ag-specific CD8+ T cell population in different tissues. Vaccine, 2004, 22, 1390-1394.	3.8	14
48	Porcine Carboxypeptidase B. Arsanilazocarboxypeptidase, Spectral and Functional Consequences of Modification of Tyrosine-"248". FEBS Journal, 1972, 25, 483-490.	0.2	13
49	Preventive and therapeutic vaccination with PAP-3, a novel human prostate cancer peptide, inhibits carcinoma development in HLA transgenic mice. Cancer Immunology, Immunotherapy, 2006, 56, 217-226.	4.2	13
50	Optimized dendritic cell vaccination induces potent CD8 T cell responses and anti-tumor effects in transgenic mouse melanoma models. Oncolmmunology, 2018, 7, e1445457.	4.6	13
51	The use of [35S]methionine as a target cell label in long term cytotoxic assays. Journal of Immunological Methods, 1992, 149, 255-260.	1.4	12
52	Immunogenicity of H-2Kb-low affinity, high affinity, and covalently-bound peptides in anti-tumor vaccination. Immunology Letters, 1999, 70, 21-28.	2.5	12
53	T cell vaccination induces the elimination of EAE effector T cells: Analysis using GFP-transduced, encephalitogenic T cells. Journal of Autoimmunity, 2010, 35, 135-144.	6.5	11
54	Coupling presentation of MHC class I peptides to constitutive activation of antigen-presenting cells through the product of a single gene. International Immunology, 2011, 23, 453-461.	4.0	11

#	Article	IF	CITATIONS
55	Modification of PDGFα receptor expression or function alters the metastatic phenotype of 3LL cells. Oncogene, 1997, 15, 1545-1554.	5.9	10
56	The human ISG12a gene is a novel caspase dependent and p53 independent pro-apoptotic gene, that is overexpressed in breast cancer. Cell Biology International Reports, 2013, 20, 37-46.	0.6	10
57	H-2Db gene transfer into highly metastatic D122 cells results in tumor rejection in allogeneic recipients, but does not affect metastasis in syngeneic recipients. Implications for mechanisms of allorejection. International Journal of Cancer, 1992, 52, 771-777.	5.1	8
58	Production of LacZ Inducible T Cell Hybridoma Specific for Human and Mouse gp10025–33 Peptides. PLoS ONE, 2013, 8, e55583.	2.5	8
59	Optimizing Tâ€cell receptor avidity with somatic hypermutation. International Journal of Cancer, 2019, 145, 2816-2826.	5.1	8
60	Electrophoretic mobility of membrane fragments on a sucrose gradient. Analytical Biochemistry, 1979, 92, 228-232.	2.4	6
61	Mouse Dendritic Cells Pulsed with Capsular Polysaccharide Induce Resistance to Lethal Pneumococcal Challenge: Roles of T Cells and B Cells. PLoS ONE, 2012, 7, e39193.	2.5	6
62	The expression of PDGF-α but not PDGF-β receptors is suppressed in Swiss/3T3 fibroblasts over-expressing protein kinase C-α. FEBS Letters, 1994, 342, 165-170.	2.8	5
63	Expression of FasL by tumor cells does not abrogate anti-tumor CTL function. Immunology Letters, 2004, 91, 119-126.	2.5	5
64	Interleukinâ€6: Effects on Tumor Models in Mice and on the Cellular Regulation of Transcription Factor IRFâ€1a. Annals of the New York Academy of Sciences, 1995, 762, 342-356.	3.8	5
65	Tâ€cell seeding: neonatal transfer of antiâ€myelin basic protein Tâ€cell lines renders Fischer rats susceptible later in life to the active induction of experimental autoimmune encephalitis. Immunology, 2009, 128, 92-102.	4.4	5
66	A universal antiâ€cancer vaccine: Chimeric invariant chain potentiates the inhibition of melanoma progression and the improvement of survival. International Journal of Cancer, 2019, 144, 909-921.	5.1	5
67	Avidity optimization of a MAGEâ€A1â€specific TCR with somatic hypermutation. European Journal of Immunology, 2021, 51, 1505-1518.	2.9	5
68	IFN \hat{l}^3 secretion following stimulation with total tumor peptides from autologous human tumors. Journal of Immunological Methods, 2000, 241, 61-68.	1.4	4
69	mRNA-based dendritic cell immunization improves survival in ret transgenic mouse melanoma model. Oncolmmunology, 2016, 5, e1160183.	4.6	4
70	Fertility Impairment and Improved Fetal Survival Induced by a Tumor Cell Line in Mice. American Journal of Reproductive Immunology, 1991, 26, 47-52.	1.2	3
71	Antigenicity and Immunogenicity of an Intracellular Delivery System of Major Histocompatibility Complex Class I Epitopes That Bypasses Proteasome Processing. Journal of Immunotherapy, 2000, 23, 622-630.	2.4	3
72	Differentiation patterns of CD4CD8 thymocyte subsets in cocultures of fetal thymus and lymphohemopoietic cells from c-fos transgenic and normal mice. Cellular Immunology, 1992, 141, 279-292.	3.0	2

#	Article	IF	Citations
73	Development of novel genetic cancer vaccines based on membrane $\hat{a}\in \hat{a}$ ttached \hat{l}^2 (sub>2microglobulin. Annals of the New York Academy of Sciences, 2013, 1283, 87-90.	3.8	2
74	Oncogenes and Tyrosine Kinase Activities as a Function of the Metastatic Phenotype., 1986,, 57-70.		2
75	Curing Metastases? Gene and Peptide Therapy. Current Topics in Microbiology and Immunology, 1996, 213 (Pt 3), 85-100.	1.1	2
76	On the development of a neoantigen vaccine for the prevention of Lynch Syndrome. International Journal of Cancer, 2022, , .	5.1	2
77	Immunogenic capacity of macrophage hybridomas. European Journal of Immunology, 1989, 19, 89-96.	2.9	1
78	Induction of antitumor immunity by proteasome-inhibited syngeneic fibroblasts pulsed with a modified TAA peptide., 2000, 85, 236-242.		1
79	T-cell subset analysis of 3LL tumor growth. International Journal of Cancer, 1991, 47, 69-72.	5.1	O
80	Tumor-Associated Antigen Peptides as Anti-Metastatic Vaccines. International Journal of Peptide Research and Therapeutics, 1998, 5, 323-328.	0.1	0
81	Tumor-associated antigen peptides as anti-metastatic vaccines. International Journal of Peptide Research and Therapeutics, 1998, 5, 323-328.	0.1	O
82	Anti-Tumor Vaccination in Heterozygous Congenic F1 Mice: Presentation of Tumor-Associated Antigen by the Two Parental Class I Alleles. Journal of Immunotherapy, 2000, 23, 344-352.	2.4	0
83	The Role of Platelet Derived Growth Factor (PDGF) and Its Receptors in Cancer and Metastasis. , 2001, , 167-186.		0
84	Antigen-Specific Antitumor Vaccination: Immunotherapy Versus Autoimmunity., 2000,, 397-408.		0
85	Adoptive Transfer of Colon Cancer Derived Peptide-specific CD8 ⁺ T Cells in HHD Mice. Immune Network, 2004, 4, 31.	3.6	0